[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
Feb 28, 2024 → Jan 15, 2025
NCT ID
NCT06302140About [14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets
[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets is a phase 1 stage product being developed by Viracta Therapeutics for Advanced Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT06302140. Target conditions include Advanced Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06302140 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Cancer